SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Earnings for SIGA Technologies, Inc. (SIGA)
Earnings in 2023 (TTM): $87.78 M
According to SIGA Technologies, Inc.'s latest financial reports the company's current earnings (TTM) are $87.78 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of SIGA Technologies, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $87.78 M | $68.07 M |
| 2022 | $44.13 M | $33.9 M |
| 2021 | $89.31 M | $69.45 M |
| 2020 | $73.51 M | $56.34 M |
| 2019 | $-10,178,423 | $-7,241,147 |
| 2018 | $411.64 M | $421.81 M |
| 2017 | $-38,329,274 | $-36,235,484 |
| 2016 | $-39,684,076 | $-39,697,960 |
| 2015 | $-38,989,341 | $-39,451,324 |
| 2014 | $-211,934,870 | $-265,463,138 |
| 2013 | $-24,795,772 | $-17,177,333 |
| 2012 | $-22,372,306 | $-14,528,153 |
| 2011 | $-22,437,470 | $13.59 M |
| 2010 | $-19,400,000 | $-28,195,339 |
| 2009 | $-17,617,939,000 | $-17,617,939 |
| 2008 | $-8,599,377 | $-8,599,377 |
| 2007 | $-5,638,557 | $-5,638,557 |
| 2006 | $-9,898,708 | $-9,898,708 |
| 2005 | $-2,287,550 | $-2,287,550 |
| 2004 | $-12,059,867 | $-9,373,319 |
| 2003 | $-5,431,646 | $-5,276,640 |
| 2002 | $ | $-3,331,027 |
| 2001 | $-3,654,191 | $-3,729,606 |
| 2000 | $-7,239,125 | $-7,789,589 |
| 1999 | $ | $-3,600,000 |
| 1998 | $-6,500,000 | $-6,600,000 |
| 1997 | $ | $-2,200,000 |
| 1996 | $-2,300,000 | $-2,300,000 |